Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
DataMEDS AIMEDS -3.35% FCF Margin % is -231.92% as of Mar. 2026. The stock has 6 warning signs investors should review. Among 118 Medical Distribution companies, DataMEDS AI ranks worse than 96.61% on this metric.
FCF Margin % is calculated as Free Cash Flow divided by its Revenue. DataMEDS AI's Free Cash Flow for the
three
months ended in Mar. 2026 was $-3.62 Mil. DataMEDS AI's Revenue for the
three
months ended in Mar. 2026 was $1.56 Mil. Therefore, DataMEDS AI's FCF Margin % for the quarter that ended in Mar. 2026 was -231.92%.
The historical rank and industry rank for DataMEDS AI's FCF Margin % or its related term are showing as below:
MEDS'
s FCF Margin % Range Over the Past 10 Years
Min: -97.85 Med: -29.57 Max: -8.84
Current: -97.85
During the past 4 years, the highest FCF Margin % of DataMEDS AI was -8.84%. The lowest was -97.85%. And the median was -29.57%.
MEDS's FCF Margin % is ranked worse than 96.61% of 118
companies
in the Medical Distribution industry
Industry Median: 0.965
vs MEDS: -97.85
DataMEDS AI FCF Margin % Related Terms
DataMEDS AI FCF Margin % Historical Data
* Premium members only.
The historical data trend for DataMEDS AI's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Distribution subindustry, DataMEDS AI's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
DataMEDS AI FCF Margin % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, DataMEDS AI's FCF Margin % distribution charts can be found below:
* The bar in red indicates where DataMEDS AI's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DataMEDS AI (MEDS) has a FCF Margin % of -231.92% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on DataMEDS AI and its competitors. According to the industry distribution chart, DataMEDS AI ranks #114 out of 118 companies in the Medical Distribution industry, placing it in the top 96.6%.
Is DataMEDS AI's FCF Margin % too high?
DataMEDS AI's current FCF Margin % is -231.92%. Based on the distribution chart, DataMEDS AI ranks #114 out of 118 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers.
How does DataMEDS AI's FCF Margin % compare to HEWA and BLMH?
According to the Medical Distribution industry distribution chart, DataMEDS AI ranks #114 out of 118 companies for FCF Margin %. This places DataMEDS AI in the lower half of its industry. The industry median FCF Margin % is 0.97. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Medical Distribution company?
The median FCF Margin % among Medical Distribution companies is 0.97, based on 118 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on DataMEDS AI and its competitors. For the Medical Distribution industry, the median FCF Margin % is 0.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. DataMEDS AI's current FCF Margin % is -231.92%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DataMEDS AI stock overvalued right now?
DataMEDS AI (MEDS) has a current FCF Margin % of -231.92%. The current FCF Margin % is -231.92%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For DataMEDS AI (MEDS), the current FCF Margin % is -231.92% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Wellgistics Health Inc is a healthcare technology and pharmaceutical logistics company. It simplifies the logistics of prescription fulfillment from the manufacturer and provider to the patient. The company seeks to be a micro health ecosystem, with a portfolio comprising a pharmacy, wholesale operations, and a technology division that provides a novel platform for hub and clinical services. It is focused on improving the lives of patients while delivering solutions for pharmacies, providers, pharmaceutical manufacturers, and payors.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEDS has been successfully added to your 
